Stocktoria
PDS Biotechnology Corp PDSB
PDS Biotechnology Corp financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D expense | $19.0M | $22.6M | $27.8M | $29.4M | $11.3M | $7.9M | $6.1M | $830,744 | $34.3M | $24.8M |
| Operating income | -$31.5M | -$36.3M | -$43.0M | -$41.7M | -$21.4M | -$14.9M | -$21.0M | -$3.6M | -$52.0M | -$39.5M |
| Interest expense | — | — | $4.2M | $1.3M | $0 | $0 | $33,559 | $3,595 | $2.2M | $1.2M |
| Income tax | -$1.2M | -$869,169 | -$1.4M | -$1.2M | -$4.5M | $0 | -$381,513 | $0 | -$2.6M | -$1.8M |
| Net income | -$34.5M | -$37.6M | -$42.9M | -$40.9M | -$16.9M | -$14.8M | -$7.0M | -$3.8M | -$50.9M | -$38.8M |
| EPS (diluted) | $-0.74 | $-1.03 | $-1.39 | $-1.43 | $-0.66 | $-0.89 | — | — | — | — |
| Operating cash flow | -$27.8M | -$35.0M | -$33.6M | -$25.7M | -$12.5M | -$13.1M | -$18.1M | -$1.6M | -$40.7M | -$32.2M |
| Free cash flow | -$27.8M | -$35.1M | -$33.6M | — | — | — | — | -$1.6M | -$40.9M | -$32.9M |
| Cash & equivalents | $26.7M | $41.7M | $56.6M | $73.8M | $65.2M | $28.8M | $12.2M | $103,695 | $88.1M | $106.4M |
| Total assets | $30.5M | $45.4M | $59.4M | $77.0M | $67.2M | $30.9M | $14.5M | $164,431 | $92.6M | $110.9M |
| Total liabilities | $21.2M | $26.4M | $33.3M | $33.0M | $4.0M | $3.8M | $2.8M | $2.2M | — | — |
| Shareholders' equity | $9.3M | $19.0M | $26.1M | $44.0M | $63.2M | $27.1M | $11.7M | -$2.1M | -$609,528 | $89.3M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.